Beyond Weight Loss: Pleiotropic Effects of GLP-1 Receptor Agonists — A Narrative Review
DOI:
https://doi.org/10.12775/JEHS.2026.95.76671Keywords
Glucagon-Like Peptide-1 Receptor Agonists; Semaglutide; Tirzepatide; Exercise; Body Composition; Cardiovascular DiseasesAbstract
Abstract
Introduction and purpose. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, were introduced for glycaemic control and weight reduction, but a rapidly expanding body of evidence shows benefits that extend far beyond the scale. The purpose of this narrative review is to synthesise current evidence on the pleiotropic effects of GLP-1 RAs across cardiovascular, renal, hepatic, respiratory, neurological and addiction-related domains, and to examine the impact of these agents on body composition and the role of physical activity in preserving skeletal muscle.
Description of the state of knowledge. Landmark randomised trials demonstrate reductions in major adverse cardiovascular events (SELECT, SUSTAIN-6, SOUL), slowed progression of chronic kidney disease (FLOW), resolution of metabolic dysfunction-associated steatohepatitis (ESSENCE) and marked improvement in obstructive sleep apnoea (SURMOUNT-OSA). These effects are only partly explained by weight loss and glucose lowering, implicating direct anti-inflammatory and tissue-protective mechanisms. A key limitation is that roughly one quarter of total weight lost is lean mass; evidence indicates that resistance and combined exercise can substantially attenuate this loss and preserve physical function.
Summary. GLP-1 RAs have evolved into multi-organ cardiometabolic therapies. Combining pharmacotherapy with structured physical activity, particularly resistance training, appears essential to optimise the quality of weight loss and preserve muscle, linking pharmacology with exercise science.
Keywords: Glucagon-Like Peptide-1 Receptor Agonists; Semaglutide; Tirzepatide; Exercise; Body Composition; Cardiovascular Diseases
References
1. Rosen CJ, Ingelfinger JR. GLP-1 receptor agonists. N Engl J Med. 2026. Online ahead of print. https://doi.org/10.1056/nejmra2500106
2. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026. Online ahead of print. https://doi.org/10.1016/s0140-6736(25)02105-1
3. Drucker DJ. The expanding landscape of GLP-1 medicines. Nat Med. 2026. Online ahead of print. https://doi.org/10.1038/s41591-025-04124-5
4. Kittleson MM, Benjamin EJ, Blumer V, et al. 2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology. J Am Coll Cardiol. 2025. Online ahead of print. https://doi.org/10.1016/j.jacc.2025.05.008
5. Saeed ZI, Apovian CM. Semaglutide and tirzepatide for the treatment of obesity and weight-related comorbidities: a narrative review. Curr Atheroscler Rep. 2025. https://doi.org/10.1007/s11883-025-01369-w
6. Kong F, Zhao Y, Zhang W, et al. Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. Nat Commun. 2026. https://doi.org/10.1038/s41467-025-67701-9
7. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. https://doi.org/10.1056/NEJMoa2307563.
8. McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025;392:2001-2012. https://doi.org/10.1056/nejmoa2501006
9. Nicholls SJ, Pavo I, Bhatt DL, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med. 2025;393:2409-2420. https://doi.org/10.1056/nejmoa2505928
10. Sattar N, Gerstein HC, D'Alessio D, et al. Estimating the true MACE benefits from tirzepatide in SURPASS-CVOT using an imputed placebo analysis of REWIND. Diabetes Care. 2026;49(10):1771-1778. https://doi.org/10.2337/dc26-0298
11. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2025;152(19):e374-e375. https://doi.org/10.1161/circulationaha.125.075872
12. Butler J, Shah SJ, Petrie MC, et al. Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials. Lancet. 2024;403(10437):1635-1648. https://doi.org/10.1016/s0140-6736(24)00469-0
13. Kosiborod MN, Deanfield J, Pratley R, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949-961. https://doi.org/10.1016/s0140-6736(24)01643-x
14. Deanfield J, Verma S, Scirica BM, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024;404(10454):773-786.. https://doi.org/10.1016/s0140-6736(24)01498-3
15. Nauck MA, Quast DR. Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol (Lausanne). 2021;12:645566. https://doi.org/10.3389/fendo.2021.645566
16. Husain M, Bain SC, Jeppesen OK, et al. Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab. 2020;22(3):442-451. https://doi.org/10.1111/dom.13955
17. Mellbin LG, Bhatt DL, David JP, et al. Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials. Eur Heart J. 2024;45(15):1371-1382. https://doi.org/10.1093/eurheartj/ehae028
18. Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121. https://doi.org/10.1056/nejmoa2403347
19. Mann JFE, Rossing P, Bakris G, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30(10):2849-2856. https://doi.org/10.1038/s41591-024-03133-0
20. Tuttle KR, Mann JFE, Mayrdorfer MM, et al. Kidney and survival outcomes with semaglutide by CKD severity in the FLOW trial. Clin J Am Soc Nephrol. 2026. Online ahead of print. https://doi.org/10.2215/cjn.0000000974
21. Alicic RZ, Neumiller JJ, Tuttle KR. GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease. Nat Rev Nephrol. 2026. Online ahead of print. https://doi.org/10.1038/s41581-025-01036-y
22. Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839-848. https://doi.org/10.1056/nejmoa1616011
23. Mann JFE, Hansen T, Idorn T, et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(11):880-893. https://doi.org/10.1016/s2213-8587(20)30313-2
24. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131-138. https://doi.org/10.1016/s0140-6736(19)31150-x
25. Colhoun HM, Lingvay I, Brown PM, et al. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial. Nat Med. 2024;30(7):2058-2066. https://doi.org/10.1038/s41591-024-03015-5
26. Shaman AM, Bain SC, Bakris GL, et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER. Circulation. 2022;145(8):575-585. https://doi.org/10.1161/circulationaha.121.055459
27. Mann JFE, Badve SV, Baeres FMM, et al. Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis. Lancet Diabetes Endocrinol. 2026. Online ahead of print. https://doi.org/10.1016/s2213-8587(26)00134-8
28. Kidney Disease: Improving Global Outcomes (KDIGO) New Guideline for Diabetes Management in Chronic Kidney Disease: A Meet-the-Expert-Session. EMJ Diabetes, Oct. 2020. https://doi.org/10.33590/emjdiabet/201014
29. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-3090. https://doi.org/10.2337/dci22-0027
30. Apperloo EM, Gorriz JL, Soler MJ, et al. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial (SMART). Nat Med. 2025;31(1):278-285. https://doi.org/10.1038/s41591-024-03327-6
31. Cooper ME, van Raalte DH. GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity. J Clin Invest. 2025. Online ahead of print. https://doi.org/10.1172/jci194749
32. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392:2089-2099. https://doi.org/10.1056/nejmoa2413258
33. Bansal MB, Patton H, Morgan TR, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD practice guidance. Hepatology. 2025. Online ahead of print. https://doi.org/10.1097/hep.0000000000001608
34. Targher G, Valenti L, Byrne CD. Metabolic dysfunction-associated steatotic liver disease. N Engl J Med. 2025. Online ahead of print. https://doi.org/10.1056/nejmra2412865
35. Jara M, Norlin J, Kjær MS, et al. Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis. Nat Med. 2025. Online ahead of print. https://doi.org/10.1038/s41591-025-03799-0
36. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193-1205. https://doi.org/10.1056/nejmoa2404881
37. Malhotra A, Grunstein R, Azarbarzin A, et al. Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial. Nat Med. 2026;32(2):653-659. https://doi.org/10.1038/s41591-025-04071-1
38. Harris A, Kaffenberger T. Glucagon-like peptide-1 receptor agonists for obstructive sleep apnea: a review. JAMA Otolaryngol Head Neck Surg. 2026. Online ahead of print. https://doi.org/10.1001/jamaoto.2026.2266
39. Plutzky J, Bogdański P, Colhoun HM, et al. Effect of semaglutide on the inflammatory biomarker high-sensitivity CRP in patients with established cardiovascular disease and overweight or obesity in SELECT: a prespecified secondary analysis. Circulation. 2026. Online ahead of print. https://doi.org/10.1161/circulationaha.125.074482
40. Wong CK, Drucker DJ. Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits. J Clin Invest. 2025. Online ahead of print. https://doi.org/10.1172/jci194751
41. Cummings JL, Atri A, Sano M, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026;407(10544):2167-2179. https://doi.org/10.1016/s0140-6736(26)00459-9
42. Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S. The promise of GLP-1 receptor agonists for neurodegenerative diseases. J Clin Invest. 2026. Online ahead of print. https://doi.org/10.1172/jci194745
43. Leiter S, Mahlknecht P, Poewe W. Recent developments in the drug treatment of Parkinson's disease. Drugs. 2026. Online ahead of print. https://doi.org/10.1007/s40265-026-02327-9
44. Vijiaratnam N, Girges C, Auld G, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK (Exenatide-PD3): a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025. Online ahead of print. https://doi.org/10.1016/s0140-6736(24)02808-3
45. Chen Y, Zhang Z, Liu Z, et al. GLP-1 receptor agonists in Parkinson's disease: a meta-analysis revealing motor benefit and highlighting mood improvement. Front Neurol. 2026. Online ahead of print. https://doi.org/10.3389/fneur.2026.1858507
46. Klausen MK, Justesen SK, Pedersen JN, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet. 2026. Online ahead of print. https://doi.org/10.1016/s0140-6736(26)00305-3
47. Cai M, Choi T, Xie Y, Al-Aly Z. Glucagon-like peptide-1 receptor agonists and risk of substance use disorders among US veterans with type 2 diabetes: cohort study. BMJ. 2026. Online ahead of print. https://doi.org/10.1136/bmj-2025-086886
48. Farokhnia M, Leggio L. Prospects of GLP-1 therapies for addiction and mental health comorbidities—quo vadis? A review. JAMA Psychiatry. 2026. Online ahead of print. https://doi.org/10.1001/jamapsychiatry.2025.4308
49. Laverde LP, Muñoz-Velandia OM, Alfonso D, Gómez Medina AM. Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials. Int J Obes (Lond). 2026. Online ahead of print. https://doi.org/10.1038/s41366-026-02118-y
50. Jobanputra R, Sargeant JA, Plekhanova T, et al. The effects of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors on lean body mass in humans: a systematic review and meta-analysis of randomised controlled trials. Diabetes Metab Res Rev. 2026. Online ahead of print. https://doi.org/10.1002/dmrr.70194
51. Eisa N, Barood O. Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2026. Online ahead of print. https://doi.org/10.1111/dom.70666
52. Karakasis P, Patoulias D, Fragakis N, Mantzoros CS. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis. Metabolism. 2025;164:156104. https://doi.org/10.1016/j.metabol.2024.156113
53. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. https://doi.org/10.1111/dom.16275
54. Busk-Cirera L, Carlsen IØ, Madsen LB, et al. Effects of incretin-based therapies, diet and exercise interventions, and bariatric surgery on fat-free mass in adults with overweight or obesity: a systematic review and meta-analysis. Diabetes Obes Metab. 2026;28(9):7737-7751. https://doi.org/10.1111/dom.71006
55. Linge J, Birkenfeld AL, Neeland IJ. Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation. 2024;150(16):1288-1298. https://doi.org/10.1161/circulationaha.124.067676
56. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. Obesity. 2025. Online ahead of print. https://doi.org/10.1016/j.obpill.2025.100181
57. Lundgren JR, Janus C, Jensen SBK, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined (S-LiTE). N Engl J Med. 2021;384(18):1719-1730. https://doi.org/10.1056/nejmoa2028198
58. Jensen SBK, Fiorenza M, Juhl CR, et al. Physical fitness with exercise and GLP-1 receptor agonist treatment alone or combined after diet-induced weight loss: a secondary analysis of a randomized controlled trial in adults with obesity. Sports Med. 2026. Online ahead of print. https://doi.org/10.1007/s40279-025-02386-0
59. Jensen SBK, Sørensen V, Sandsdal RM, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2024;7(6):e2416775. https://doi.org/10.1001/jamanetworkopen.2024.16775
60. Ruder K. At ObesityWeek, more data and questions about semaglutide, tirzepatide, and retatrutide. JAMA. 2024;332(23):1961-1963. https://doi.org/10.1001/jama.2023.23141
61. Lieberman DE, Aslan DH, Heymsfield SB. The conundrum of exercise for weight management in the GLP-1 receptor agonist era. JAMA. 2026. Online ahead of print. https://doi.org/10.1001/jama.2026.5537
62. Mehrtash F, Dushay J, Manson JE. I am taking a GLP-1 weight-loss medication—what should I know? JAMA Intern Med. 2025;185(9):1131. https://doi.org/10.1001/jamainternmed.2025.1133
63. Swift DL, Ross LM, Laddu DR, et al. Role of physical activity in obesity treatment and cardiometabolic health: a scientific statement from the American Heart Association. Circulation. 2026. Online ahead of print. https://doi.org/10.1161/cir.0000000000001441
64. Jakicic JM, Apovian CM, Barr-Anderson DJ, et al. Physical activity and excess body weight and adiposity for adults: American College of Sports Medicine consensus statement. Med Sci Sports Exerc. 2024;56(10):2076-2091. https://doi.org/10.1249/mss.0000000000003520
65. Dobbie LJ, Tolvanen L, Alves D, et al. Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO consensus statement. Lancet Diabetes Endocrinol. 2026. Online ahead of print. https://doi.org/10.1016/s2213-8587(26)00122-1
66. Pratley RE, Denham DS, Trivedi R, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2026;32(7):2673-2678. https://doi.org/10.1038/s41591-026-04440-4
67. Locatelli JC, Costa JG, Haynes A, et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care. 2024;47(10):1718-1730. https://doi.org/10.2337/dci23-0100
68. Prokopidis K. Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: risks beyond muscle mass reductions. Br J Pharmacol. 2026. Online ahead of print. https://doi.org/10.1111/bph.70355
69. Kunutsor SK, Seidu S. Safety and tolerability of glucagon-like peptide-1 receptor agonists: a state-of-the-art narrative review. Drugs. 2026. Online ahead of print. https://doi.org/10.1007/s40265-025-02263-0
70. Batsis JA, Gavras A, Gross DC, et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med. 2026. Online ahead of print. https://doi.org/10.7326/annals-25-00478
71. Sukurica E, Sengul GF, Uysal Cinar F. Weight loss or muscle loss? Cellular mechanisms and clinical strategies for preserving lean mass during GLP-1-based therapy. Diabetes Obes Metab. 2026. Online ahead of print. https://doi.org/10.1111/dom.71422
72. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. https://doi.org/10.1056/nejmoa2032183
73. Moiz A, Peters TM, Tsoukas MA, et al. Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making. EClinicalMedicine. 2026. Online ahead of print. https://doi.org/10.1016/j.eclinm.2026.103991
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Szymon Pieczara, Paulina Musiał, Wojciech Nowicki, Damian Machaj, Mikołaj Stańko, Zofia Stefanik, Piotr Urbanowicz

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 4
Number of citations: 0